NAV

Sulfaisodimidine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Sulfaisodimidine
DrugBank Accession Number
DB13283
Background

Sulfaisodimidine also called sulfisomidine is an antibacterial product that has been studied for the treatment of urinary tract infections in the 1950s, however, it is unclear whether this drug has been officially approved for use anywhere 1.

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 278.33
Monoisotopic: 278.083746881
Chemical Formula
C12H14N4O2S
Synonyms
  • solfisomidina
  • Sulfisomidine
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Sulfaisodimidine.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be increased when used in combination with Sulfaisodimidine.
AlbiglutideThe therapeutic efficacy of Albiglutide can be increased when used in combination with Sulfaisodimidine.
AlogliptinThe therapeutic efficacy of Alogliptin can be increased when used in combination with Sulfaisodimidine.
BenzylpenicillinSulfaisodimidine may decrease the excretion rate of Benzylpenicillin which could result in a higher serum level.
Food Interactions
Not Available

Categories

ATC Codes
J01EB01 — Sulfaisodimidine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aminobenzenesulfonamides. These are organic compounds containing a benzenesulfonamide moiety with an amine group attached to the benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzenesulfonamides
Direct Parent
Aminobenzenesulfonamides
Alternative Parents
Benzenesulfonyl compounds / Aniline and substituted anilines / Pyrimidines and pyrimidine derivatives / Organosulfonamides / Imidolactams / Heteroaromatic compounds / Aminosulfonyl compounds / Azacyclic compounds / Primary amines / Organopnictogen compounds
show 2 more
Substituents
Amine / Aminobenzenesulfonamide / Aminosulfonyl compound / Aniline or substituted anilines / Aromatic heteromonocyclic compound / Azacycle / Benzenesulfonyl group / Heteroaromatic compound / Hydrocarbon derivative / Imidolactam
show 13 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
sulfonamide, pyrimidines, sulfonamide antibiotic (CHEBI:32166)
Affected organisms
Not Available

Chemical Identifiers

UNII
W03L3ODK6E
CAS number
515-64-0
InChI Key
YZMCKZRAOLZXAZ-UHFFFAOYSA-N
InChI
InChI=1S/C12H14N4O2S/c1-8-7-12(15-9(2)14-8)16-19(17,18)11-5-3-10(13)4-6-11/h3-7H,13H2,1-2H3,(H,14,15,16)
IUPAC Name
4-amino-N-(2,6-dimethylpyrimidin-4-yl)benzene-1-sulfonamide
SMILES
CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC(C)=N1

References

General References
  1. BOGASH M, ELLIS H, MURPHY JJ: Elkosin in the management of urinary tract infections. J Am Med Assoc. 1956 Aug 18;161(16):1564-5. [Article]
ChemSpider
5150
RxNav
10206
ChEBI
32166
ChEMBL
CHEMBL485696
ZINC
ZINC000000056658
Wikipedia
Sulfisomidine

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.229 mg/mLALOGPS
logP0.84ALOGPS
logP0.91Chemaxon
logS-3.1ALOGPS
pKa (Strongest Acidic)6.12Chemaxon
pKa (Strongest Basic)5Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area97.97 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity73.78 m3·mol-1Chemaxon
Polarizability28.05 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-004i-0190000000-59063d6fce1efa7dd208
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-0090000000-b06eeda697d6a68ecc8d
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a59-3910000000-0fd61e3c25e73bfb073c
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-0290000000-ab703f6f95c4460151ad
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-02fy-9600000000-4e6fe411f8cc374653d1
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0gbc-9230000000-ce54c90f56675d39e17e
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-178.9114585
predicted
DarkChem Lite v0.1.0
[M-H]-163.197
predicted
DeepCCS 1.0 (2019)
[M+H]+179.6777585
predicted
DarkChem Lite v0.1.0
[M+H]+165.55501
predicted
DeepCCS 1.0 (2019)
[M+Na]+179.2146585
predicted
DarkChem Lite v0.1.0
[M+Na]+171.64815
predicted
DeepCCS 1.0 (2019)

Drug created at June 23, 2017 20:39 / Updated at June 12, 2020 16:53